Haemostasis in Medical Technology

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced today that it will present clinical and preclinical data on its oral Factor Xa inhibitor and on its intravenous and oral ADP receptor antagonist at the XXI Congress of the International Society of Thrombosis...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary sy...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced positive Phase II data on its lead compound, PRT054021, an oral Factor Xa inhibitor, today at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland. The EXPERT t...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Societ...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results from the RE-NOVATE(TM) trial demonstrated that oral dabigatran etexilate once daily, administered for an average of 33 days, was non-inferior to enoxaparin, also administered for an average of 33 days, in preventing venous thromboemb...

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

...gs were presented today at the XXII International Society on Thrombosis and haemostasis Congress in Boston. Edoxaban is being developed solely by Daiichi Sankyo C...ic medicinal products in non-surgical patients. Journal of Thrombosis and haemostasis 2005;3: 692-694. ...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

...of Leuven will present additional data from the earlier successful Phase I studies at the XXII Congress of the International Society on Thrombosis and haemostasis (ISTH) on July 15, 2009 in Boston. Patrik De Haes, CEO of ThromboGenics commented, "We are very happy that this important study with TB-402 is ...

Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes

... Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that ma...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

...t al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and haemostasis 2005;3: 692-694. 2. Jorgensen, H.S., Nakayama, H, Reith, J. et. al. Acute stroke with atrial fibrillation. Stroke 1996;27: 1765-1769. ...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

...ncluding the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that ma...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

...ncing the compound into further clinical trials. Data from EXPERT will be presented at the XXI Congress of the International Society on Thrombosis and haemostasis in Geneva, Switzerland (July 6-12, 2007). "There is a tremendous need for a once a day, oral anticoagulant to replace and improve upon current thera...

Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

...alog compounds under development for non-ophthalmic indications. Dr. Mousa's talk will be presented at the XXI International Society on Thrombosis and haemostasis (ISTH) Congress in Geneva, Switzerland on July 9, 2007. The ISTH holds its congress every other year and the organization includes 2,800 thrombosis, h...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

...ncluding the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that ma...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

...cluding the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that m...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...ial data presented today at the XXI International Society on Thrombosis and haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior e...- presented at ISTH in 2005, and published in the Journal of Thrombosis and haemostasis in 2005 and 2006, and the additional once-daily ODIXa HIP study published i...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...Bleeding Rates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban (Xarelto®) achieved superior efficacy in the prevention of venous thromboembolism (VTE) in...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

...ents at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study presented today at the XXIst International Society on Thrombosis and haemostasis (ISTH) congress in Geneva. VTE is a preventable disease which contributes significantly to morbidity and mortality among patients hospitalized for a...

New Information on the Potential of Plasmin Shared at ISTH Congress

...AL-05-00018, was presented by Talecris Biotherapeutics, Inc. (http://www.talecris.com) this week at the XXIst International Society for Thrombosis and haemostasis (ISTH) Congress in Geneva, Switzerland. The information included new data and updates on continuing research and development of Plasmin as a potential...